University of Cambridge > > Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer > A tumoral stromal cell that mediates immune suppression

A tumoral stromal cell that mediates immune suppression

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Katrien Van Look.

The finding by Boon of the Cancer-Testis Antigen family of tumor-associated antigens in 1991 enabled therapeutic cancer vaccination to be rigorously tested. Despite vaccination with peptides, recombinant proteins, and viral vectors expressing CT antigens, which induced antigen-specific T cells, control of tumor growth has not been achieved. Studies in humans and in mice suggest that this outcome is caused by immune suppression within the tumor microenvironment. Stromal cells of the innate and adaptive immune systems have been thought to mediate this suppression, and less attention has been given to mesenchymal stromal cells. We have generated mice that permit the conditional ablation of a stromal cell type of presumed mesenchymal origin that is found in all human adenocarcinomas and other examples of “healing wounds”. The loss of this stromal cell type, which comprises only ~2% of all tumoral cells, leads to regression of an established immunogenic tumor. Control of the development or function of this stromal cell in human tumors may improve the efficacy of therapeutic cancer vaccines.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity